Novo Nordisk A/S (NYSE:NVO) Upgraded to Market Perform at Sanford C. Bernstein

Novo Nordisk A/S (NYSE:NVO) was upgraded by equities researchers at Sanford C. Bernstein from an “underperform” rating to a “market perform” rating in a research note issued on Monday, Marketbeat Ratings reports.

NVO has been the subject of a number of other research reports. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Stock Performance

NVO opened at $83.19 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market capitalization of $373.32 billion, a price-to-earnings ratio of 26.92, a PEG ratio of 1.37 and a beta of 0.45. The company has a fifty day moving average of $101.94 and a 200 day moving average of $120.27. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors have recently made changes to their positions in NVO. International Assets Investment Management LLC raised its position in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the period. DSM Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after buying an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S in the third quarter worth approximately $98,765,000. Marshall Wace LLP raised its holdings in shares of Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after buying an additional 689,441 shares during the period. Finally, Wellington Management Group LLP bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $42,017,000. Institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.